$RDGL .006 this #biotech has limitless POTENTIAL I
Post# of 4506
(Total Views: 577)
Posted On: 07/28/2018 3:27:55 PM
$RDGL .006 this #biotech has limitless POTENTIAL I would notbe surprised to see it break $5 sometime in its future and I'm being very honest. An investor recently purchased over 5 million shares! Do your due diligence, the more you read the more you will understand. BIG MONEY traders LOADING HEAVY. VOLUME has gone up over 20x. Don't sleep.
https://www.slideshare.net/…/advanced-medic...e-corp-…
$RDGL TOP 5 MUST READS! All from Page 1 of the FORM S-1 filing with the Securities and Exchange Commission on February 8 , 2018, link included right below this.....
https://backend.otcmarkets.com/…/sec-…/12...ntent/html
1) Radiogel approved to treat feline sarcomas and canine soft tissue sarcomas, which is the most common type of cancer in animals"
2) Battelle has granted us an exclusive license to patents covering the manufacturing, processing and applications of RadioGel™ (the “ Battelle License ”). Other intellectual property protection for RadioGel™ includes proprietary production processes and trademark protection in 17 countries. We plan to continue efforts to develop new refinements on the production process, and the product and application hardware, as a basis for future patents."
3) A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting early in 2019. The safety review at UC Davis is almost completed. They will be treating prostate and liver cancer in dogs in 2019."
4) These animal therapies will focus on creating labels that describe the procedures in detail as a guide to future veterinarians. The labels will be voluntarily submitted to the FDA for review. They will then be used as data for future FDA applications in the medical sector and as key intellectual property for licensing to private veterinary clinics.
5)We anticipate that future profit will be derived from direct sales of RadioGel™ and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally.
Business Summary
Heres the full Page 1 excerpts: As filed with the Securities and Exchange Commission on February 8 , 2018
https://backend.otcmarkets.com/…/sec-…/12...ntent/html
"Our IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospitals to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. In January 2018, we received notification from the FDA that the Center for Veterinary Medicine Product Classification Group ruled that RadioGel™ is classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas, which is the most common type of cancer in animals. In addition, the FDA also reviewed and approved our label, which is a requirement for any device used in animals.
"RadioGel™ incorporates patented technology developed for Battelle Memorial Institute (“ Battelle ”) at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers. Battelle has granted us an exclusive license to patents covering the manufacturing, processing and applications of RadioGel™ (the “ Battelle License ”). Other intellectual property protection for RadioGel™ includes proprietary production processes and trademark protection in 17 countries. We plan to continue efforts to develop new refinements on the production process, and the product and application hardware, as a basis for future patents."
"We have worked with four different university veterinarian hospitals on RadioGel™ testing and therapy. Colorado State University demonstrated the procedures and the CT and PET-CT imaging of RadioGel. Washington State University treated four cats for feline sarcoma. They concluded that the product was safe and effective in killing cancer cells. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting early in 2019. The safety review at UC Davis is almost completed. They will be treating prostate and liver cancer in dogs in 2019."
These animal therapies will focus on creating labels that describe the procedures in detail as a guide to future veterinarians. The labels will be voluntarily submitted to the FDA for review. They will then be used as data for future FDA applications in the medical sector and as key intellectual property for licensing to private veterinary clinics.
https://www.slideshare.net/RedChip/advanced-m...L/376/RDGL
https://www.slideshare.net/…/advanced-medic...e-corp-…
$RDGL TOP 5 MUST READS! All from Page 1 of the FORM S-1 filing with the Securities and Exchange Commission on February 8 , 2018, link included right below this.....
https://backend.otcmarkets.com/…/sec-…/12...ntent/html
1) Radiogel approved to treat feline sarcomas and canine soft tissue sarcomas, which is the most common type of cancer in animals"
2) Battelle has granted us an exclusive license to patents covering the manufacturing, processing and applications of RadioGel™ (the “ Battelle License ”). Other intellectual property protection for RadioGel™ includes proprietary production processes and trademark protection in 17 countries. We plan to continue efforts to develop new refinements on the production process, and the product and application hardware, as a basis for future patents."
3) A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting early in 2019. The safety review at UC Davis is almost completed. They will be treating prostate and liver cancer in dogs in 2019."
4) These animal therapies will focus on creating labels that describe the procedures in detail as a guide to future veterinarians. The labels will be voluntarily submitted to the FDA for review. They will then be used as data for future FDA applications in the medical sector and as key intellectual property for licensing to private veterinary clinics.
5)We anticipate that future profit will be derived from direct sales of RadioGel™ and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally.
Business Summary
Heres the full Page 1 excerpts: As filed with the Securities and Exchange Commission on February 8 , 2018
https://backend.otcmarkets.com/…/sec-…/12...ntent/html
"Our IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospitals to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. In January 2018, we received notification from the FDA that the Center for Veterinary Medicine Product Classification Group ruled that RadioGel™ is classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas, which is the most common type of cancer in animals. In addition, the FDA also reviewed and approved our label, which is a requirement for any device used in animals.
"RadioGel™ incorporates patented technology developed for Battelle Memorial Institute (“ Battelle ”) at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers. Battelle has granted us an exclusive license to patents covering the manufacturing, processing and applications of RadioGel™ (the “ Battelle License ”). Other intellectual property protection for RadioGel™ includes proprietary production processes and trademark protection in 17 countries. We plan to continue efforts to develop new refinements on the production process, and the product and application hardware, as a basis for future patents."
"We have worked with four different university veterinarian hospitals on RadioGel™ testing and therapy. Colorado State University demonstrated the procedures and the CT and PET-CT imaging of RadioGel. Washington State University treated four cats for feline sarcoma. They concluded that the product was safe and effective in killing cancer cells. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting early in 2019. The safety review at UC Davis is almost completed. They will be treating prostate and liver cancer in dogs in 2019."
These animal therapies will focus on creating labels that describe the procedures in detail as a guide to future veterinarians. The labels will be voluntarily submitted to the FDA for review. They will then be used as data for future FDA applications in the medical sector and as key intellectual property for licensing to private veterinary clinics.
https://www.slideshare.net/RedChip/advanced-m...L/376/RDGL
(0)
(0)